Wall Street analysts expect that ICU Medical, Incorporated (NASDAQ:ICUI) will report $1.47 earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for ICU Medical’s earnings. The highest EPS estimate is $1.61 and the lowest is $1.32. ICU Medical reported earnings of $1.12 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 31.3%. The business is scheduled to report its next quarterly earnings results on Thursday, November 8th.

On average, analysts expect that ICU Medical will report full-year earnings of $8.48 per share for the current year, with EPS estimates ranging from $8.35 to $8.60. For the next fiscal year, analysts anticipate that the company will post earnings of $9.95 per share, with EPS estimates ranging from $9.87 to $10.03. Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for ICU Medical.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, August 9th. The medical instruments supplier reported $2.66 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.82 by $0.84. ICU Medical had a net margin of 5.93% and a return on equity of 12.78%. The business had revenue of $360.46 million during the quarter, compared to analysts’ expectations of $337.60 million. During the same quarter in the prior year, the business posted $0.76 earnings per share. ICU Medical’s revenue was up 8.7% compared to the same quarter last year.

Several research firms recently weighed in on ICUI. BidaskClub cut shares of ICU Medical from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 19th. ValuEngine cut shares of ICU Medical from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 3rd. Zacks Investment Research raised shares of ICU Medical from a “hold” rating to a “strong-buy” rating and set a $311.00 price objective for the company in a research report on Wednesday, May 16th. Finally, TheStreet cut shares of ICU Medical from an “a” rating to a “c+” rating in a research report on Wednesday, May 9th. One equities research analyst has rated the stock with a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Strong Buy” and an average target price of $337.00.

In other news, Director Pfizer Inc sold 700,000 shares of the stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $284.35, for a total value of $199,045,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director George A. Lopez sold 33,000 shares of the stock in a transaction dated Wednesday, June 6th. The stock was sold at an average price of $292.38, for a total transaction of $9,648,540.00. Following the completion of the transaction, the director now directly owns 426,016 shares of the company’s stock, valued at approximately $124,558,558.08. The disclosure for this sale can be found here. Insiders have sold 879,244 shares of company stock valued at $252,331,743 in the last ninety days. 12.50% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new position in shares of ICU Medical in the fourth quarter worth about $366,000. Advantus Capital Management Inc acquired a new position in shares of ICU Medical in the first quarter valued at approximately $468,000. Barrett Asset Management LLC increased its stake in shares of ICU Medical by 5.7% in the second quarter. Barrett Asset Management LLC now owns 39,325 shares of the medical instruments supplier’s stock valued at $11,548,000 after buying an additional 2,110 shares during the period. MetLife Investment Advisors LLC increased its stake in shares of ICU Medical by 139.1% in the first quarter. MetLife Investment Advisors LLC now owns 16,197 shares of the medical instruments supplier’s stock valued at $4,088,000 after buying an additional 9,422 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of ICU Medical by 11.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 80,237 shares of the medical instruments supplier’s stock valued at $20,252,000 after buying an additional 8,486 shares during the period. 72.73% of the stock is owned by hedge funds and other institutional investors.

ICUI traded up $0.65 on Friday, hitting $294.40. 127,900 shares of the stock were exchanged, compared to its average volume of 147,231. ICU Medical has a 12 month low of $167.76 and a 12 month high of $321.70. The stock has a market capitalization of $5.94 billion, a price-to-earnings ratio of 53.12 and a beta of 0.36.

About ICU Medical

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Further Reading: What is the NASDAQ?

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.